Lipid-Lowering Effect and Efficacy After Switching to Etravirine in HIV-Infected Patients With Intolerance to Suppressive HAART

REFERENCES

• Grinspoon SK, Grunfeld C, Kotler DP, et al. State of the science conference. Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/ AIDS: executive summary. Circulation. 2008;118:198–210.
   PubMed Web of Science ®Google Scholar
• Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289: 2978–2982.
   PubMed Web of Science ®Google Scholar
• Anastos K, Lu D, Shi Q, et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr. 2007;45:34–42.
   PubMed Web of Science ®Google Scholar
• Fisac C, Fumero E, Crespo M, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS. 2005;19:917–925.
   PubMed Web of Science ®Google Scholar
• Negredo E, Ribalta J, Paredes R, et al. Reversal of ath-erogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevi-rapine. AIDS. 2002;16:1383–1389.
   PubMed Web of Science ®Google Scholar
• Negredo E, Cruz L, Paredes R, et al. Virological, immu-nological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis. 2002;34:504–510.
   PubMed Web of Science ®Google Scholar
• Martinez E, Conget I, Lozano L, et al. Reversion of meta-bolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS. 1999;13:805–810.
   PubMed Web of Science ®Google Scholar
• Negredo E, Ribalta J, Ferrer E, et al. Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV infected patients. AIDS. 2004;18:819–821.
   PubMed Web of Science ®Google Scholar
• Van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiret-roviral therapy naive patients infected with HIV-1. PLoS Med. 2004;1:e19.
   PubMed Web of Science ®Google Scholar
• Van Leth F, Phanuphak P, Ruxrungtham K, et al. Compari-son of first line antiretroviral therapy with regimens includ-ing nevirapine, efavirenz or both drugs, plus stavudine and lamivudine: a randomized open label trial, the 2NN study. Lancet. 2004;363:1253–1263.
   PubMed Web of Science ®Google Scholar
• Riddler SA, Haubrich R, DiRienzo G, et al. Class sparing regimens for initial treatment of HIV-1 infection. N Eng J Med. 2008;358:2095–2106.
   PubMed Web of Science ®Google Scholar
• Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment experienced HIV infected patients: pooled 48 weeks analysis of two randomized controlled trials. AIDS. 2009;23:2289–2300.
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Pro-gram Expert Panel on Detection, Evaluation, and Treat-ment of High Blood Cholesterol in Adults (Adult Treatment Pane III) final report. Circulation. 2002;106:3143–3421.
   PubMed Web of Science ®Google Scholar
• National Health Institute. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. 2004. http://www.nlaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/daidsaegradingtable.pdf.
   Google Scholar
• Dobiasova M, Frohlich J. The plasma parameter log (TC/HDL-c) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma. Clin Biochem. 2001;34: 583–588.
   PubMed Web of Science ®Google Scholar
• Raffi F, Bonnet B, Ferré V, et al. Substitution of a non-nucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA. Clin Infect Dis. 2000;31:1274–1278.
   PubMed Web of Science ®Google Scholar
• Parienti JJ, Massari V, Rey D, et al. Efavirenz to nevi-rapine switch in HIV-1 infected patients with dyslipid-emia: a randomized, controlled study. Clin Infect Dis. 2007;45:263–266.
   PubMed Web of Science ®Google Scholar
• Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral ther-apy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN study (A1424–097) 48 weeks results. Clin Infect Dis. 2007;44:1484–1492.
   PubMed Web of Science ®Google Scholar
• Rubio R, Serrano O, Carmena J, et al. Effect of simplifica-tion from protease inhibitors to boosted atazanavir-based regimen in real life conditions. HIV Med. 2010;11:545–553.
   PubMed Web of Science ®Google Scholar
• Martinez E, Larrousse M, Llibre J, et al; for the SPIRAL Study Group. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS. 2010;24:1697–1707.
   PubMed Web of Science ®Google Scholar
• Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised con-trolled trials. Lancet. 2010;375:396–407.
   PubMed Web of Science ®Google Scholar
• Squires KE, Young B, Dejesus E, et al. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritona-vir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS. 2010;24:2019–2027.
   PubMed Web of Science ®Google Scholar
• Aberg JA, Tebas P, Overton ET, et al. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treat-ment-naive, HIV type 1-infected subjects over 48 weeks [published online ahead of print April 2,2012]. AIDS Res Human Retroviruses. 2012; 28.
   Web of Science ®Google Scholar
• Fatkenheuer G, Duvivier C, Rieger A, et al. Lipid profiles for etravirine versus efavirenz in treatment naïve patients in the randomized double blind SENSE trial. J Antimicrob Chemother. 2012;67:685–690.
   PubMed Web of Science ®Google Scholar
• Waters L, Fisher M, Winston A, et al. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individu-als receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS. 2012;25: 65–71.
   Web of Science ®Google Scholar
• Nguyen A, Calmy A, Delhumeau C, et al. A randomized crossover study to compare efavirenz and etravirine treat-ment. AIDS. 201125: 57–63.
   Google Scholar
• Falcone EL, Mangili A, Skinner S, et al. Framingham risk score and early markers of atherosclerosis in a cohort of adults infected with HIV. Anti vir Ther. 201116: 1–8.
   Google Scholar
• Worm SW, Kamara DA, Reiss P, et al. Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS. 2011;25:1497–1504.
   PubMed Web of Science ®Google Scholar